OFG
VRTX icon

OmniStar Financial Group’s Vertex Pharmaceuticals VRTX Stock Holding History

OmniStar Financial Group’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q2 		– Sell
-108
Closed -$26K – 305
2020
Q1 		$26K Buy
+108
New +$24.8K 0.03% 165

Other funds holding VRTX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

OmniStar Financial Group's VRTX Position: Q2 2020 in Review

OmniStar Financial Group sold out of Vertex Pharmaceuticals (VRTX) in Q2 2020, closing a stake of 108 shares — an estimated $26K sold.

OmniStar Financial Group first reported a position in VRTX in Q1 2020 and held it in 1 quarter. The position peaked at $26K in Q1 2020. 964 funds tracked by Wall St. Rank hold VRTX as of Q2 2020.

  • OmniStar Financial Group reported no remaining Vertex Pharmaceuticals position as of Q2 2020 after selling out during the quarter.
  • OmniStar Financial Group sold 108 Vertex Pharmaceuticals shares in Q2 2020, an estimated $26K.
  • OmniStar Financial Group first reported a position in Vertex Pharmaceuticals in Q1 2020 and held it in 1 quarter.
  • OmniStar Financial Group's Vertex Pharmaceuticals position peaked at $26K in Q1 2020.
  • 964 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q2 2020.

Based on OmniStar Financial Group's 13F filing for Q2 2020, filed 6 Jul 2020.